<DOC>
	<DOCNO>NCT01284478</DOCNO>
	<brief_summary>The purpose study determine sustain steroid delivery system ( Ozurdex , Allergan ) safe effective treat Cystoid Macular Edema diabetic patient Cataract Surgery</brief_summary>
	<brief_title>Ozurdex Combined Pseudophakic Cystoid Macular Edema Diabetic Macular Edema After Cataract Surgery</brief_title>
	<detailed_description />
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Capsule Opacification</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>DIABETIC PATIENTS WHO DEVELOP CYSTOID MACULA EDEMA AFTER CATARACT SURGERY ( WITHIN 410 WEEKS AFTER SURGERY VISUAL ACUITY WORSE THAN 20/32 VISUAL ACUITY WORSE THAN 20/200 MODERATE OR SEVERE GLAUCOMA ( AS DEFINED AS USING &gt; 2 TOPICAL GLAUCOMA MEDIATIONS . USE OF SYSTEMIC , PERIOCULAR OR INTRAOCULAR CORTICOSTEROIDS WITHIN 30 DAYS OF ENROLLMENT</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>pseudophakic cystoid macular edema , diabetic macular edema , Irvine Gass Syndrome , cataract surgery , ozurdex , dexamethasone</keyword>
</DOC>